Recombinant Human Serum Albumin Market

Recombinant Human Serum Albumin Market – Overview

Human serum albumin (HSA) is accountable for a variety of biological functions, including molecule and substance binding and delivery to the cell. It also functions as an antioxidant and a ligand transporter. HSA is widely used in hospitals and clinics to treat various ailments including hypoproteinemia, hemorrhagic shock, cirrhotic ascites, severe burns, and foetal erythroblastosis. Despite its multiple uses, high safety risks associated with the meager rate of human donor turnouts, continuous shortage in supply, and the risk of transmission of blood-borne contaminants such as prions, viruses, and mycoplasma have led to the development of recombinant technology to design and produce HSA from various plant and animal sources. The increasing cases of hepatitis and HIV among other plasma related issues are projected to aid in expansion of the global recombinant human serum albumin market during the forecast period, set between 2021 and 2031.

The global recombinant human serum albumin market is categorized on the basis of source, application, end user, and region. Based on source, the market is grouped into pichia pastoris, oryza sativa, and others such as saccharomyces cerevisiae, etc. In terms of segmentation by application, the market is categorized into cryopreservation, drug formulations, stem cell therapy, cryopreservation, cell culture media, and others such as stabilization of vaccines, and others.

The research report on the recombinant human serum albumin market offers a 360-degree overview of the market and factors boosting or repelling its growth. This includes drivers, restraints, challenges, and future growth opportunities. List of the players operating in this market and their efforts to obtain a significant position in the market competition in terms of innovations and new product launches is also discussed in details. It also focuses on the recent developments and innovations that helped the market grow in terms of revenue generation. The impact of the novel COVID19 pandemic is also discussed in the report. For more information on the report, refer to the company website.

Recombinant Human Serum Albumin Market – Competitive Landscape

The nature of competition for this market is fragmented owing to the presence of a few players. Leading players of the recombinant human serum albumin market are engaging in joint ventures and merger strategies to gain an upper hand in the overall market competition. Others are investing in introduction of innovative products to attract more revenues to the market. The key objective is to ensure a significant position in the market competition and earn high revenues for the overall market.

Some of the key players of the global recombinant human serum albumin market include:

• Thermo Fischer Scientific Inc.
• Mitsubishi Tanabe Pharma Corporation
• Wuhan Healthgen Biotechnology Corp
• Albumin Therapeutics LLC
• Novozyme A/S
• Sigma-Aldrich Co. LLC
• Prospec-Tany TechnoGame Ltd.
• Medxbio Pte. Ltd.
• Merck KGaA
• Others

Recombinant Human Serum Albumin Market - Growth Drivers

Recombinant albumin is used as an active ingredient in the production of bio therapeutics as a substitute for human serum albumin. Aside from avoiding the spread of serum-derived disease agents, it also provides benefits for example improved consistency between batches. In the coming years, these factors are likely to shift demand away from conventional human serum albumin and toward recombinant albumin. The use of recombumin HSA in marketed vaccines and in research laboratories will also help create revenue generating opportunities for the recombinant human serum albumin market in the forecast period.

Recombinant Human Serum Albumin Market – Geographical Insights

Geographically, this market is widespread into the regions of Latin America, Europe, North America, and the Middle East and Africa. These regions are further categorized as per the nations bringing business. North America emerged as the largest revenue generators for the Recombinant Human Serum Albumin market on account of the presence of major players, coupled with well-established healthcare infrastructure. Besides this, the increasing use of these serums in research and development activities and the presence of well-equipped research facilities in the developing nations such as India, China, and others are projected to help Asia Pacific emerge as the fastest growing market for recombinant human serum albumin market in the forecast period.